Mentari Names Greg Divis CEO, Sets Migraine Drug Filing Timelines Ahead of InMed Merger
INM has more than doubled off its 52-week low of $0.575.
Summary
Mentari Therapeutics appointed former Avadel CEO Greg Divis to lead the company ahead of its merger with InMed, and set regulatory filing timelines for its migraine prevention pipeline.
Key Events · M&A and Partnerships · INM
-
CEO Appointment
Mentari named Greg Divis as CEO effective July 20, 2026. Divis previously led Avadel through FDA approval and a $2.4B sale to Alkermes.
-
Pipeline Timelines
MT-001 (anti-PACAP antibody) regulatory filing expected in mid-2026; MT-002 (bispecific antibody) filing in Q1 2027.
-
Merger Context
The appointment and pipeline updates come as InMed and Mentari work toward closing their all-stock reverse merger, announced May 19, 2026.
-
Leadership Credibility
Divis brings over 30 years of industry experience, including commercializing Lumryz and leading Avadel's transformation into a fully integrated commercial organization.
Analysis · INM · Life Sciences
Mentari, the private company merging with InMed, appointed industry veteran Greg Divis as CEO. Divis previously led Avadel through FDA approval and a $2.4B sale to Alkermes, signaling a leadership upgrade as the combined company prepares for key regulatory milestones. Mentari also disclosed that its lead migraine drug MT-001 is on track for a regulatory filing in mid-2026, with a bispecific antibody MT-002 following in Q1 2027. These updates add credibility to the merger's value proposition and provide concrete near-term catalysts, though the transaction still faces shareholder votes and financing risks.
At the time of this filing, INM was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.58 to $2.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.